8M Float
8% Short
$386 M market cap
Offering complete Feb 12
Looks like AUTL may be breaking out of it's downtrend soon. I picked up a position on Feb 12.
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Autolus Therapeutics today and set a price target of $18.00. The company’s shares closed last Friday at $7.29.
According to TipRanks.com,...
AUTL: Autolus Therapeutics plc
2019-11-05 09:10:33
Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO1 for Treatment of Acute Lymphoblastic Leukemia
